259 related articles for article (PubMed ID: 21985184)
1. Infliximab restores the balance between pro- and anti-apoptotic proteins in regressing psoriatic lesions.
Kokolakis G; Giannikaki E; Stathopoulos E; Avramidis G; Tosca AD; Krüger-Krasagakis S
Br J Dermatol; 2012 Mar; 166(3):491-7. PubMed ID: 21985184
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U
Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388
[TBL] [Abstract][Full Text] [Related]
4. Nature of cell kinetics in psoriatic epidermis.
Doger FK; Dikicioglu E; Ergin F; Unal E; Sendur N; Uslu M
J Cutan Pathol; 2007 Mar; 34(3):257-63. PubMed ID: 17302610
[TBL] [Abstract][Full Text] [Related]
5. Influence of infliximab on keratinocyte apoptosis in psoriasis patients.
Raho G; Vena GA; Bizzoca A; Cassano N; Garofalo E; Congedo M; Gennarini G
Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):227-31. PubMed ID: 20507213
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis.
El-Domyati M; Barakat M; Abdel-Razek R; El-Din Anbar T
Int J Dermatol; 2007 May; 46(5):468-74. PubMed ID: 17472673
[TBL] [Abstract][Full Text] [Related]
7. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
8. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of apoptosis regulatory proteins in response to PUVA therapy for psoriasis.
El-Domyati M; Moftah NH; Nasif GA; Abdel-Wahab HM; Barakat MT; Abdel-Aziz RT
Photodermatol Photoimmunol Photomed; 2013 Feb; 29(1):18-26. PubMed ID: 23281693
[TBL] [Abstract][Full Text] [Related]
10. Effect of vitamin D3 on the increased expression of Bcl-xL in psoriasis.
Fukuya Y; Higaki M; Higaki Y; Kawashima M
Arch Dermatol Res; 2002 Feb; 293(12):620-5. PubMed ID: 11875645
[TBL] [Abstract][Full Text] [Related]
11. The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis.
Adişen E; Gülekon A; Erdem O; Dursun A; Gürer MA
J Eur Acad Dermatol Venereol; 2006 May; 20(5):527-33. PubMed ID: 16684279
[TBL] [Abstract][Full Text] [Related]
12. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
Lizzul PF; Aphale A; Malaviya R; Sun Y; Masud S; Dombrovskiy V; Gottlieb AB
J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
[TBL] [Abstract][Full Text] [Related]
14. Expression of Bcl-2 family proteins in psoriasis.
Batinac T; Zamolo G; Hadzisejdić I; Zauhar G; Brumini G; Ruzić A; Persić V
Croat Med J; 2007 Jun; 48(3):319-26. PubMed ID: 17589974
[TBL] [Abstract][Full Text] [Related]
15. Etanercept does not have an apoptosis-inducing effect on psoriatic keratinocytes.
Tatlican S; Arikok A; Gulbahar O; Eren C; Cevirgen B; Eskioglu F
J Dermatolog Treat; 2010 Sep; 21(5):306-10. PubMed ID: 19878038
[TBL] [Abstract][Full Text] [Related]
16. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
17. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
18. Combined effect of tumor necrosis factor (TNF)-alpha and heat shock protein (HSP)-70 in reducing apoptotic injury in hypoxia: a cell culture study.
Goel G; Guo M; Ding J; Dornbos D; Ali A; Shenaq M; Guthikonda M; Ding Y
Neurosci Lett; 2010 Oct; 483(3):162-6. PubMed ID: 20691248
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
Smit JV; de Jong EM; van Hooijdonk CA; Otero ME; Boezeman JB; van de Kerkhof PC
J Am Acad Dermatol; 2004 Aug; 51(2):257-64. PubMed ID: 15280845
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study.
Abdou AG; Hanout HM
J Cutan Pathol; 2008 May; 35(5):445-51. PubMed ID: 18005174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
